Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH018 combined with toripalimab in advanced solid tumors
CTR20221589Phase 2Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gfh018, toripalimab in Nonhematologic neoplasms, sponsored by GenFleet Therapeutics. Started Aug 2022; status: completed.
02
Drugs
gfh018toripalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221589.